Latest news with #HengruiPharma
Mint
28-07-2025
- Business
- Mint
Jiangsu Hengrui Pharma stock spikes 10% to 4-year high on drug development deal with GSK – here's what the company does
Shares of Jiangsu Hengrui Pharmaceuticals Company, a Chinese pharmaceutical firm, jumped 10% to hit a 4-year high of 61-yuan, equivalent to USD 9.62 on the Shanghai Stock Exchange (SSE), after the company announced that it had agreed to license the global rights of its HRS-9821 drug and 11 other programs to GlaxoSmithKline Intellectual Property (GSK). The programs were selected to complement GSK's extensive Respiratory, Immunology & Inflammation (RI&I), and Oncology pipeline, having been assessed for their potential best-in-class or first-in-class profiles. The agreements include an exclusive worldwide license (excluding mainland China, Hong Kong, Macau, and Taiwan) for a potential best-in-class PDE3/4 inhibitor (HRS-9821), which is in clinical development for the treatment of chronic obstructive pulmonary disease (COPD) as an add-on maintenance treatment, regardless of background therapy, GSK said in its filing on Monday. The British pharmaceutical giant added that HRS-9821 supports its ambition to treat patients across the widest spectrum of COPD, including those who experience continued dyspnea (shortness of breath) or are unlikely to receive inhaled corticosteroids or biologics, based on their disease profile. The agreements also feature a pioneering, large-scale collaboration to develop up to 11 additional programs besides HRS-9821, each with its own financial structure. Hengrui Pharma will lead the development of these programs up to the completion of Phase I trials, including trials involving patients outside of China. GSK will have the exclusive option to further develop and commercialize each program worldwide (excluding mainland China, Hong Kong, Macau, and Taiwan) at the end of Phase I or earlier, at its discretion, and will also have program substitution rights. GSK has agreed to pay $500 million in upfront fees across the agreements, including for the license of the PDE3/4 program. The potential total value of future success-based development, regulatory, and commercial milestone payments to Hengrui Pharma could reach approximately $12 billion if all programs are optioned and all milestones are met. Additionally, Hengrui Pharma will be eligible for tiered royalties on global product net sales (excluding mainland China, Hong Kong, Macau, and Taiwan). The license to HRS-9821 remains subject to customary conditions, including regulatory clearance under the Hart-Scott-Rodino Act in the United States. Tony Wood, Chief Scientific Officer at GSK, said, 'We're delighted to announce these exciting agreements with Hengrui Pharma, which complement our already extensive pipeline. This deal reflects our strategic investment in programs that address validated targets, increasing the likelihood of success, while giving us the option to advance the assets with the greatest potential for patient impact.' Founded in 1970, Hengrui Pharma is a global pharmaceutical company dedicated to research, development, and commercialization of high-quality medicines to address unmet clinical needs. With a global R&D network of 14 centers and over 5,500 professionals, Hengrui's therapeutic focus includes oncology, metabolic and cardiovascular diseases, immunological and respiratory disorders, and neuroscience. To date, Hengrui has commercialized 23 new molecular entity drugs and 4 other innovative drugs in China. Disclaimer: The views and recommendations given in this article are those of individual analysts. These do not represent the views of Mint. We advise investors to check with certified experts before taking any investment decisions.
Yahoo
28-07-2025
- Business
- Yahoo
Hengrui Pharma and GSK link across key therapeutic areas
Hengrui Pharma has signed an agreement with GSK for the development of up to 12 innovative medicines across several therapeutic areas, including respiratory, immunology and inflammation, and oncology. The collaboration is poised to enhance Hengrui's globalisation strategy and provide GSK with significant growth opportunities beyond 2031. GSK will pay an upfront fee of $500m, which includes licensing for the phosphodiesterase (PDE)3/4 programme. The potential value of future success-based payments to Hengrui Pharma could be close to $12bn, assuming all programmes are optioned and milestones met. Hengrui Pharma is also set to receive tiered royalties on worldwide product net sales, with certain regional exclusions. A highlight of the agreement is the worldwide licence for HRS-9821, a PDE3/4 inhibitor in clinical development for chronic obstructive pulmonary disease (COPD). HRS-9821 aligns with GSK's goal to address a broad spectrum of COPD patients, including those with ongoing dyspnoea or those less likely to be prescribed inhaled corticosteroids or biologics. In early trials, this inhibitor showed positive anti-inflammatory and bronchodilation effects. Its potential for a dry-powder inhaler formulation could integrate well with GSK's existing inhaled portfolio. Hengrui Pharma executive vice-president and chief strategy officer Frank Jiang stated: 'GSK brings additional research and development expertise, a robust global clinical network and broad regulatory capabilities that will accelerate our PDE3/4 inhibitor as well as an array of other innovative therapy programmes to overseas markets, potentially delivering breakthrough treatments to patients globally." Beyond HRS-9821, the collaboration includes up to 11 additional programmes. Hengrui Pharma will spearhead the development up to Phase I trials, after which GSK may opt to develop further and commercialise the programmes globally, excluding mainland China, the Macau special administrative region (SAR), Hong Kong SAR and Taiwan. This scaled collaboration is designed to expedite the development of innovative medicines, leveraging GSK's expertise and global reach alongside Hengrui Pharma's discovery and clinical evaluation capabilities. The licensing of HRS-9821 is contingent upon customary regulatory clearances, including under the Hart-Scott-Rodino Act in the US. In March 2025, MSD entered an exclusive licence agreement with Hengrui Pharma for the investigational oral small-molecule lipoprotein(a) [Lp(a)] inhibitor, HRS-5346. "Hengrui Pharma and GSK link across key therapeutic areas" was originally created and published by Pharmaceutical Technology, a GlobalData owned brand.
Yahoo
28-07-2025
- Business
- Yahoo
Hengrui Pharma and GSK enter agreements to develop up to 12 innovative medicines across Respiratory, Immunology & Inflammation and Oncology
Includes license for potential best-in-class PDE3/4 inhibitor (HRS-9821) in clinical development for treatment of COPD Additional 11 programmes to be developed by Hengrui Pharma and optioned by GSK following phase I completion JIANGSU, China, July 27, 2025 /PRNewswire/ -- Hengrui Pharma ( today announced it has entered into agreements with GSK plc (LSE/NYSE: GSK) to develop up to 12 innovative medicines, adding significant value to the globalization strategy of Hengrui and significant new growth opportunities to GSK beyond 2031. The programmes were selected to complement GSK's extensive Respiratory, Immunology & Inflammation (RI&I) and Oncology pipeline, and assessed for their potential best- or first-in-class profiles. GSK will pay $500 million in upfront fees across the agreements. The agreements include an exclusive worldwide license (excluding mainland China, Hong Kong SAR, Macau SAR and Taiwan region) for a potential best-in-class, PDE3/4 inhibitor (HRS-9821) in clinical development for the treatment of chronic obstructive pulmonary disease (COPD) as an add-on maintenance treatment, irrespective of background therapy. The addition of HRS-9821 supports GSK's ambition to treat patients across the widest spectrum of COPD by including those who face continued dyspnoea (shortness of breath) or who are unlikely to receive inhaled corticosteroids or biologics, based on their disease profile. HRS-9821 has demonstrated potent PDE3 and PDE4 inhibition, leading to increased bronchodilation and anti-inflammatory effects in early clinical and preclinical studies. In addition, HRS-9821 provides the opportunity for a convenient dry-powder inhaler (DPI) formulation that strategically fits GSK's established inhaled portfolio. The agreements also include a pioneering scaled collaboration to generate up to 11 programmes in addition to HRS-9821, each with its own financial structure. Hengrui Pharma will lead the development of these programmes up to completion of phase I trials, including patients outside of China. GSK will have the exclusive option to further develop and commercialise each programme worldwide (excluding mainland China, Hong Kong SAR, Macau SAR and Taiwan region), at the end of phase I or earlier at GSK's election as well as certain programme substitution rights. Frank Jiang, Executive Vice President and Chief Strategy Officer of Hengrui Pharma, said: "This strategic collaboration with GSK marks yet another significant milestone in Hengrui's globalisation journey and our mission to innovate and deliver higher-quality, cutting-edge therapies for patients worldwide. GSK brings additional R&D expertise, a robust global clinical network, and broad regulatory capabilities that will accelerate our PDE3/4 inhibitor as well as an array of other innovative therapy programs to overseas markets, potentially delivering breakthrough treatments to patients globally." Tony Wood, Chief Scientific Officer, GSK said: "We're delighted to announce these exciting agreements with Hengrui Pharma which complement our already-extensive pipeline. This deal reflects our strategic investment in programmes that address validated targets, increasing the likelihood of success, and with the option to advance those assets with the greatest potential for patient impact." The collaboration enables scale and speed to proof-of-concept to develop up to 11 additional innovative medicines. It benefits from GSK's therapy area expertise, deep understanding of disease biology, clinical development capability and global commercial scale with Hengrui Pharma's early discovery engine, platform technologies, extensive pre-clinical pipeline of high-value programmes and speed of clinical evaluation. Financial considerations GSK will pay $500 million in upfront fees across the agreements including for the license of the PDE3/4 programme. The potential total value of future success-based development, regulatory and commercial milestone payments to Hengrui Pharma is approximately $12 billion if all programmes are optioned and all milestones are achieved. In addition, Hengrui Pharma will be eligible to receive tiered royalties on global product net sales (excluding mainland China, Hong Kong SAR, Macau SAR and Taiwan region). The license to HRS-9821 is subject to customary conditions, including applicable regulatory agency clearances under the Hart-Scott-Rodino Act in the US. About GSKGSK is a global biopharma company with a purpose to unite science, technology, and talent to get ahead of disease together. Find out more at About Hengrui PharmaHengrui Pharma is an innovative, global pharmaceutical company dedicated to the research, development and commercialisation of high-quality medicines to address unmet clinical needs. With a global R&D team that includes 14 R&D centres and more than 5,500 professionals, Hengrui Pharma's therapeutic areas of focus include oncology, metabolic and cardiovascular diseases, immunological and respiratory diseases, and neuroscience. To date, Hengrui has commercialised 23 new molecular entity drugs and 4 other innovative drugs in China. Founded in 1970 with the core principle of putting patients first, Hengrui Pharma remains committed to advancing human health by striving to conquer diseases, improve health, and extend lives through the power of science and technology. Media on behalf of Hengrui Pharma:DGA Grouphengrui@ View original content: SOURCE Jiangsu Hengrui Pharmaceuticals Co., Ltd Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
15-07-2025
- Business
- Yahoo
Hengrui Pharma and Kailera Therapeutics Report Positive Topline Data from Phase 3 Obesity Trial in China of Dual GLP-1/GIP Receptor Agonist HRS9531
– Mean weight loss of 19.2% at 6 mg with no plateau in 48-week Phase 3 trial – – Favorable safety profile consistent with other GLP-1-based treatments – – Hengrui to submit NDA in China; Kailera plans to evaluate both higher doses and longer duration of treatment in global clinical trials – JIANGSU, China and WALTHAM, Mass., July 15, 2025 (GLOBE NEWSWIRE) -- Hengrui Pharma (Hengrui), a global pharmaceutical company focused on scientific and technological innovation, and Kailera Therapeutics, Inc. (Kailera), a clinical-stage biopharmaceutical company focused on advancing a broad pipeline of next-generation therapies for the treatment of obesity, today announced positive topline data from Hengrui's Phase 3 clinical trial (HRS9531-301) of once-weekly subcutaneous injection of HRS9531, a novel dual GLP-1/GIP receptor agonist, in individuals living with obesity or overweight in China (NCT06396429). The HRS9531-301 trial met both primary endpoints, including superior weight loss with HRS9531 (2 mg, 4 mg, and 6 mg) and greater percentage of participants achieving body weight reductions of at least 5% compared to placebo at 48 weeks. Hengrui plans to submit a New Drug Application (NDA) for chronic weight management in China, and Kailera is advancing HRS9531 as KAI-9531 to global clinical trials. The trial enrolled 567 participants with a mean baseline body weight of 93 kg (205 lb). Based on the primary analysis (treatment policy estimand)1, participants taking HRS9531 achieved a mean weight loss of up to 17.7% (16.3% placebo-adjusted). Additionally, up to 88.0% of HRS9531-treated participants achieved at least 5% weight loss, and 44.4% of participants achieved at least 20% weight loss. Based on the pre-specified supplementary analysis (hypothetical strategy estimand)2, participants taking HRS9531 achieved a mean weight loss of up to 19.2% (17.7% placebo-adjusted). The trial results demonstrated a favorable safety and tolerability profile consistent with GLP-1-based treatments and previously reported HRS9531 Phase 2 clinical data. Most treatment-emergent adverse events (TEAEs) were mild to moderate and gastrointestinal-related. In previously reported Phase 2 clinical trial results (NCT06054698), based on the primary analysis (treatment policy estimand)1, participants taking the 8 mg dose of HRS9531 achieved a mean weight loss of 22.8% (21.1% placebo-adjusted) at week 36, with no plateau in weight loss and a favorable safety profile consistent with other GLP-1-based treatments. Based on supplementary analysis (hypothetical strategy estimand)2, mean weight loss with the 8 mg dose of HRS9531 was 23.6% (21.7% placebo-adjusted). 'We are delighted to share the data from this landmark study. This is a huge step forward in providing innovative solutions to meet the needs of people living with obesity,' said Hong Chen, Head of Metabolism Department I of Hengrui Pharma. 'The positive data from the HRS9531-301 study demonstrated meaningful, sustained weight loss. With an affirmed safety and tolerability profile, we strongly believe in its potential to help more people living with obesity reach their individual weight loss goals. Based on these robust and encouraging clinical results, we are accelerating our efforts to advance this highly promising candidate. We look forward to filing for market approval in China as soon as possible to bring HRS9531 to patients struggling with obesity and overweight.' 'We commend our colleagues at Hengrui for these impressive Phase 3 clinical results, building on the strong momentum behind HRS9531 (KAI-9531). As Kailera prepares to advance KAI-9531 into a global clinical program, we look forward to evaluating both higher doses and longer duration of treatment to expand on KAI-9531's best-in-class potential,' said Ron Renaud, President and Chief Executive Officer, Kailera. 'Together with Hengrui, we believe KAI-9531 has tremendous potential to improve the lives of countless individuals worldwide, including those with higher BMIs who are seeking greater weight loss to achieve optimal health.' Hengrui intends to share the full HRS9531 Phase 3 clinical trial data at an upcoming scientific conference. About the HRS9531-301 Clinical TrialThe HRS9531-301 clinical trial was a multi-center, randomized, double-blind, placebo-controlled Phase 3 clinical study (NCT06396429) conducted by Hengrui in China to evaluate the efficacy and safety of HRS9531 injection in adults (≥18 years of age) with obesity (BMI ≥ 28 kg/m2) or overweight (BMI ≥ 24 kg/m2) and at least one weight-related comorbidity without diabetes. The study enrolled 567 participants with 531 completing the trial. The primary objective was to evaluate the efficacy of HRS9531 injection vs. placebo in reducing body weight after 48 weeks of treatment. Participants were randomized (1:1:1:1) to receive once-weekly subcutaneous injections of HRS9531 2 mg, 4 mg, 6 mg or placebo for 48 weeks. About HRS9531 (KAI-9531)HRS9531 is a novel injectable dual GLP-1/GIP receptor agonist formulated as an injectable peptide in clinical development for the treatment of type 2 diabetes, obesity and related conditions. Over 2,000 patients to date were dosed with HRS9531 across several Phase 1, Phase 2, and Phase 3 clinical trials in China. HRS9531 is being developed globally (ex-Greater China) by Kailera Therapeutics as KAI-9531. About Hengrui PharmaHengrui Pharma is an innovative, global pharmaceutical company dedicated to the research, development and commercialization of high-quality medicines to address unmet clinical needs. With a global R&D team that includes 14 R&D centers and more than 5,500 professionals, Hengrui Pharma's therapeutic areas of focus include oncology, metabolic and cardiovascular diseases, immunological and respiratory diseases, and neuroscience. To date, Hengrui has commercialized 23 new molecular entity drugs and 4 other innovative drugs in China. Founded in 1970 with the core principle of putting patients first, Hengrui Pharma remains committed to advancing human health by striving to conquer diseases, improve health, and extend lives through the power of science and technology. About Kailera TherapeuticsKailera Therapeutics (Kailera) is developing a broad, advanced, and differentiated portfolio of clinical-stage injectable and oral therapies for the treatment of obesity. Kailera's most advanced program, KAI-9531 (being developed in China as HRS9531), is an injectable dual GLP-1/GIP receptor agonist that has demonstrated positive results in clinical trials in obesity and type 2 diabetes in China. The Company is also advancing a diversified pipeline leveraging several mechanisms and routes of delivery, including oral administration. Kailera's mission is to develop next-generation weight management therapies that give people the power to transform their lives and elevate their overall health. The Company is based in Waltham, MA and San Diego, CA. For more information, visit and follow us on LinkedIn and X. 1 Based on the treatment policy estimand (primary statistical analysis): treatment effect regardless of treatment adherence2 Based on the hypothetical strategy estimand (supplementary statistical analysis): treatment effect excluding the occurrence of intercurrent events Contact Information Contact Information for Hengrui DGA Group hengrui@ Contact Information for KaileraMaura GavaghanVice President, Corporate Communications and Investor
Business Wire
08-07-2025
- Health
- Business Wire
眼科领域迎来重大突破！Hengrui的Heng Qin®（全氟己基辛烷滴眼液）获批成为首个治疗睑板腺功能障碍(MGD)相关干眼症的药物
中国江苏、德国海德堡和马萨诸塞州剑桥--(BUSINESS WIRE)--(美国商业资讯)-- 专注于科技创新的全球性制药企业Jiangsu Hengrui Pharmaceuticals Co., Ltd. ('Hengrui Pharma')与专注于研发基于独特EyeSol ® 无水技术的同类首创及最佳眼科疗法的生物制药公司Novaliq GmbH ('Novaliq')今日宣布，中国国家药品监督管理局(NMPA)已批准Heng Qin ® （全氟己基辛烷滴眼液）用于治疗与睑板腺功能障碍(MGD)相关的干眼症(DED)。Heng Qin ® 是首个且目前唯一获批用于治疗MGD相关干眼症的药物，未来数月将在中国面向患者上市。 根据《2023年中国MGD诊断与治疗专家共识》，目前尚无直接针对MGD的治疗药物 1 。《干眼诊断与治疗临床指南》显示，中国干眼症的发病率为21%-30% 2 。流行病学研究表明，69%-86%的干眼症患者属于蒸发过强型干眼症，而这一最常见的亚型主要由MGD引发 3,4 。Hengrui致力于满足临床对安全有效的MGD相关干眼症治疗药物的迫切且普遍的需求。 Heng Qin ® （全氟己基辛烷滴眼液）基于EyeSol ® 研发而成，该技术是全球首个不含水、辅料和防腐剂的药物技术 5,6 。凭借低表面张力的特性 5 ，它可以在眼表快速扩散 7 ，改善泪膜脂质层、抑制泪液蒸发并促进角膜上皮修复 8,9 。此外，全氟己基辛烷可补充脂质层中的非极性脂质，增加泪膜厚度并改善睑板腺功能 8,9 。 国家药品监督管理局对Heng Qin ® 的批准基于一项在中国患者中开展的多中心、随机、对照、双盲关键Ⅲ期临床试验 8 。研究显示，与活性对照药0.6%氯化钠溶液相比，Heng Qin ® 分别早在用药2周和第29天时显著改善了MGD相关干眼症患者的临床症状和体征。这一疗效持续至研究结束的第57天。研究结果表明，Heng Qin ® 安全性良好，耐受性佳，滴眼后眼部给药部位不良反应的发生率较低，与对照药相当。 2019年，Hengrui Pharma与Novaliq宣布达成战略合作，Hengrui Pharma获得全氟己基辛烷（研发代号：SHR8058滴眼液）在中国的独家研发、生产及商业化权利。全氟己基辛烷眼用溶液分别于2023年5月和2024年9月在美国和加拿大获批用于干眼症治疗。 关于Hengrui Pharma Jiangsu Hengrui Pharmaceuticals Co., Ltd. (Hengrui Pharma)是一家创新型全球性制药企业，致力于高品质药物的研发和商业化，以应对未获满足的临床需求。Hengrui Pharma拥有由14个研发中心和5500余名专业人员组成的全球研发团队，重点关注肿瘤、代谢及心血管疾病、免疫及呼吸系统疾病、神经科学等治疗领域。截至目前，Hengrui已在中国上市23个新分子实体药物和4个其他创新药物。Hengrui Pharma成立于1970年，秉持以患者为中心的核心理念，始终致力于通过科技力量攻克疾病、改善健康、延长生命，为人类健康事业贡献力量。 关于 Novaliq Novaliq是一家私营生物制药公司，专注于同类首创及最佳眼科治疗药物的开发。Novaliq开发的EyeSol ® 是一种新型无水外用眼科药物。两款基于EyeSol ® 技术的干眼症治疗药物Miebo ® 和Vevye ® 已获得美国食品药品管理局批准并在美国上市，为患者护理带来革新。Novaliq的研发管线为眼科和视网膜疗法提供了多种发展机会。Novaliq总部位于德国海德堡，在美国马萨诸塞州剑桥设有办事处。其长期唯一股东是dievini Hopp BioTech holding GmbH & Co. KG，该公司是生命和健康科学公司的活跃投资者。更多信息请访问 。 参考文献 亚洲干眼学会中国分会、海峡两岸医药卫生交流协会眼科专业委员会眼表与泪液疾病学组、中国医师协会眼科医师分会眼表与干眼学组（2023年）。《中华眼科杂志》。2023年11月11日；59(11), 880–887。doi: 10.3760/ 《干眼诊断与治疗临床指南》。ISBN：9787523506189 Jie Y、Xu L、Wu YY、Jonas JB。《北京眼病研究中中国成年人干眼症患病率》(Prevalence of dry eye among adult Chinese in the Beijing Eye Study)。《眼科学（伦敦）》。2009年3月；23(3):688–693。doi: 10.1038/ Lemp MA、Crews LA、Bron AJ、Foulks GN、Sullivan BD。《基于临床患者队列的水液缺乏型与蒸发过强型干眼症分布情况：一项回顾性研究》(Distribution of aqueous-deficient and evaporative dry eye in a clinic-based patient cohort: a retrospective study)。《角膜》。2012年5月；31(5):472-8。doi: 10.1097/ICO.0b013e318225415a。 Tsagogiorgas C、Otto M。《半氟化烷烃作为新型药物载体——潜在医学及临床应用概述》(Semifluorinated Alkanes as New Drug Carriers-An Overview of Potential Medical and Clinical Applications)。《药剂学》。2023年4月11日；15(4):1211。doi: 10.3390/pharmaceutics15041211。 Sheppard JD等。莫哈韦研究组。《NOV03用于治疗睑板腺功能障碍相关干眼症的症状和体征：随机Ⅲ期莫哈韦研究》(NOV03 for Signs and Symptoms of Dry Eye Disease Associated With Meibomian Gland Dysfunction: The Randomized Phase 3 MOJAVE Study)。《美国眼科学杂志》。2023年8月；252:265-274。doi: 10.1016/ Agarwal P等。《评估半氟化烷烃对眼表和泪液动力学影响的临床前研究》(Preclinical studies evaluating the effect of semifluorinated alkanes on ocular surface and tear fluid dynamics)。《眼表》。2019年4月；17(2):241-249。doi: 10.1016/ Vittitow J等。《全氟己基辛烷（一种干眼症滴眼液）的体外蒸发抑制作用》(In Vitro Inhibition of Evaporation with Perfluorohexyloctane, an Eye Drop for Dry Eye Disease)。《当代治疗研究（临床与实验）》。2023年5月12日；98:100704。doi: 10.1016/ Steven P等。《半氟化烷烃滴眼液治疗睑板腺功能障碍所致干眼症》(Semifluorinated Alkane Eye Drops for Treatment of Dry Eye Disease Due to Meibomian Gland Disease)。《眼科药物与治疗杂志》。2017年11月；33(9):678-685。doi: 10.1089/jop.2017.0042。 Tian L等。《全氟己基辛烷滴眼液治疗中国患者的睑板腺功能障碍相关干眼症：一项随机临床试验》(Perfluorohexyloctane Eye Drops for Dry Eye Disease Associated With Meibomian Gland Dysfunction in Chinese Patients: A Randomized Clinical Trial)。《美国医学会眼科杂志》。2023年4月1日；141(4):385-392。doi: 10.1001/jamaophthalmol.2023.0270。 任何产品/品牌名称和/或标识均为各自所有者的商标。© 2025 Jiangsu Hengrui Pharmaceuticals Co., Ltd.和德国海德堡Novaliq GmbH版权所有。保留所有权利。 免责声明：本公告之原文版本乃官方授权版本。译文仅供方便了解之用，烦请参照原文，原文版本乃唯一具法律效力之版本。
